- Home
- NKTR vs TSI Comparison
NKTR vs TSI Comparison
Compare NKTR & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | TSI |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 277.8M |
| IPO Year | 1996 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NKTR | TSI |
|---|---|---|
| Price | $66.82 | $4.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $146.67 | N/A |
| AVG Volume (30 Days) | ★ 511.4K | 157.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,711,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $33.40 | $4.33 |
| 52 Week High | $109.00 | $5.06 |
Technical Indicators
Market Signals| Indicator | NKTR | TSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 40.73 |
| Support Level | $64.28 | N/A |
| Resistance Level | $76.63 | $4.45 |
| Average True Range (ATR) | 2.75 | 0.05 |
| MACD | -0.86 | -0.01 |
| Stochastic Oscillator | 7.41 | 55.56 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.